• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2019 Fiscal Year Final Research Report

Innovative approach to anti-MDA5 antibody-positive dermatomyositis; Development of animal models and understanding of pathogenesis

Research Project

  • PDF
Project/Area Number 18K19532
Research Category

Grant-in-Aid for Challenging Research (Exploratory)

Allocation TypeMulti-year Fund
Review Section Medium-sized Section 53:Organ-based internal medicine and related fields
Research InstitutionThe University of Tokyo

Principal Investigator

Sato Shinichi  東京大学, 医学部附属病院, 教授 (20215792)

Co-Investigator(Kenkyū-buntansha) 吉崎 歩  東京大学, 医学部附属病院, 講師 (40530415)
Project Period (FY) 2018-06-29 – 2020-03-31
Keywords皮膚筋炎 / モデル動物 / MD5 / 自己免疫疾患
Outline of Final Research Achievements

In this study, we use complete Freund's adjuvant in MDA5-deficient mice to elicit an immune response to the full-length MDA5 peptide and adoptive transfer of immune-responsive cells such as B cells into wild-type mice to generate a mouse model of anti-MDA5 antibody-positive dermatomyositis and analyze the pathogenesis histopathologically, serologically, and cell biologically. Because MDA5 is a self-antigen, tolerance is predicted to be induced and may not be able to elicit an immune response to MDA5. Therefore, we examined whether splenocytes obtained from MDA5-deficient mice immunized with MDA5 can be transfected into wild-type mice by dividing them into T and B cell fractions and inducing pathogenesis. This experiment will also allow the identification of cells that are important for disease development.

Free Research Field

膠原病

Academic Significance and Societal Importance of the Research Achievements

これまで抗MDA5抗体陽性皮膚筋炎の研究は十分に行われていない。オーファン疾患である皮膚筋炎において、その亜型と捉えられる本疾患は患者数がごく少数に限られており、検討に足るまとまった症例数が得られないからである。また、抗MDA5抗体が病勢と相関することが知られているにも関わらず、抗MDA5抗体の病原性についても不明な点が多い。MDA5は細胞質内蛋白であり、通常抗体は細胞内には侵入しないため、抗MDA5抗体がどの蛋白をターゲットとして病原性を発揮しているかは、ブラックボックスである。本研究で挑戦したモデル動物の開発は、本疾患の解析に役立ち、病因と病態の解明への道を拓く点で意義深い。

URL: 

Published: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi